American College of Rheumatology hybrid analysis of certolizumab pegol plus methotrexate in patients with active rheumatoid arthritis: data from a 52-week phase III trial.
OBJECTIVE
The American College of Rheumatology (ACR) hybrid (a modified mean percent response to treatment) was officially recommended by the ACR as a revision to 20%, 50%, and 70% response criteria (ACR20/50/70) scores, but has not been tested in clinical trials. We performed a post hoc analysis of a phase III study of certolizumab pegol (Rheumatoid Arthritis Prevention of Structural Damage 1 [RAPID 1]) using the ACR hybrid.


METHODS
Patients with active rheumatoid arthritis were randomized to certolizumab pegol (200 mg or 400 mg every other week) plus methotrexate or placebo plus methotrexate. ACR hybrid scores were compared with ACR20/50/70 outcomes.


RESULTS
Differences between active treatment and placebo were significant throughout the study using the ACR20 and ACR hybrid outcomes. In the certolizumab pegol 200 mg group, the median ACR hybrid score at week 52 (last observation carried forward) was 49.99. A total of 258 (65.8%) of 392 and 172 (43.9%) of 392 patients had ACR20 and ACR50 responses, respectively. An additional 55 patients (14.0%) and 59 patients (15.1%) had mean improvements in ACR core measures of ≥ 20% and ≥ 50%, respectively, and therefore had positive ACR hybrid scores, despite lacking ACR20 and ACR50 responses, respectively. In the placebo group, median ACR hybrid scores were <10 at most time points; unlike other measures, the ACR hybrid measure indicated worsening scores for many patients.


CONCLUSIONS
ACR hybrid analysis had greater sensitivity than traditional ACR20/50/70 criteria, demonstrating improvements in ACR20 nonresponders treated with certolizumab pegol. Negligible benefit was observed with placebo using ACR hybrid analysis.
van Vollenhoven
R F
RF
Karolinska Institute, Stockholm, Sweden. Ronald.van.Vollenhoven@ki.se
Felson
D
D
Strand
V
V
Weinblatt
M E
ME
Luijtens
K
K
Keystone
E C
EC
D000328:Adult; D061067:Antibodies, Monoclonal, Humanized; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000473:pathology; D000068582:Certolizumab Pegol; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D007140:Immunoglobulin Fab Fragments / Q000008:administration & dosage*; D008297:Male; D008727:Methotrexate / Q000008:administration & dosage*; D011092:Polyethylene Glycols / Q000008:administration & dosage*; D012219:Rheumatology / Q000592:standards*; D012955:Societies, Medical / Q000592:standards*; D014481:United States
D061067:Antibodies, Monoclonal, Humanized; D007140:Immunoglobulin Fab Fragments; D011092:Polyethylene Glycols; D000068582:Certolizumab Pegol; D008727:Methotrexate
Curr Opin Rheumatol. 2008 May;20(3):306-13
18388523
Arthritis Rheum. 1995 Jun;38(6):727-35
7779114
N Engl J Med. 1999 Jan 28;340(4):253-9
9920948
Arthritis Rheum. 2003 Jan;48(1):35-45
12528101
Arthritis Rheum. 2003 Nov;48(11):3031-8
14613263
Arthritis Rheum. 1996 Jan;39(1):34-40
8546736
Ann Rheum Dis. 2009 Jun;68(6):797-804
19015207
Arthritis Rheum. 1993 Jun;36(6):729-40
8507213
Arthritis Rheum. 1992 May;35(5):498-502
1575785
Arthritis Rheum. 2008 Nov;58(11):3319-29
18975346
N Engl J Med. 2000 Nov 30;343(22):1594-602
11096166
Arthritis Rheum. 2004 Apr;50(4):1051-65
15077287
Arthritis Rheum. 2004 May;50(5):1400-11
15146409
Lancet. 1999 Dec 4;354(9194):1932-9
10622295
Arthritis Rheum. 2007 Mar 15;57(2):193-202
17330293